SEC Company Response from IR BIOSCIENCES HOLDINGS INC (CIK 0000793043) — Mar 1, 2005
IR BIOSCIENCES HOLDINGS INC (CIK 0000793043)
Date: March 1, 2005 · CIK: 0000793043 · Accession: 0001185185-05-000090
AI Filing Summary & Sentiment
Referenced dates: February 2, 2005
Letter
March 1, 2005 Via Edgar and Facsimile (202) 942-9638 -------------------------------------- Division of Corporation Finance Securities and Exchange Commission 450 5th Street, N.W. Washington D.C. 20549 Attn: Lillian Brown
Re: IR Biosciences Holdings, Inc. Schedule TO-I (File No. 005-40624)
Dear Ms. Brown:
Pursuant to the Commission's comment letter dated February 2, 2005 regarding the Tender Offer Statement on Schedule TO-I (File No. 005-40624) of IR Biosciences Holdings, Inc. (the "Company") initially filed with the Commission on January 24, 2005, as amended and supplemented by Amendment No. 1, filed on February 11, 2005, and Amendment No. 2, filed on February 18, 2005 (as subsequently amended and supplemented, the "Schedule TO"), the Company hereby acknowledges that:
o the Company is responsible for the adequacy and accuracy of the disclosure in the Schedule TO;
o comments of the staff of the Commission (the "Staff") or changes to disclosure in response to Staff comments in the Schedule TO reviewed by the Staff do not foreclose the Commission from taking any action with respect to the Schedule TO; and
o the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions or further comments, please do not hesitate to contact the undersigned or Katherine J. Blair at (310) 552-5000 or via fax at (310) 552-5001.
Sincerely,
/s/ Michael K. Wilhelm
Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
March 1, 2005
Via Edgar and Facsimile (202) 942-9638
--------------------------------------
Division of Corporation Finance
Securities and Exchange Commission
450 5th Street, N.W.
Washington D.C. 20549
Attn: Lillian Brown
Re: IR Biosciences Holdings, Inc.
Schedule TO-I (File No. 005-40624)
Dear Ms. Brown:
Pursuant to the Commission's comment letter dated February 2, 2005 regarding the
Tender Offer Statement on Schedule TO-I (File No. 005-40624) of IR Biosciences
Holdings, Inc. (the "Company") initially filed with the Commission on January
24, 2005, as amended and supplemented by Amendment No. 1, filed on February 11,
2005, and Amendment No. 2, filed on February 18, 2005 (as subsequently amended
and supplemented, the "Schedule TO"), the Company hereby acknowledges that:
o the Company is responsible for the adequacy and accuracy of the
disclosure in the Schedule TO;
o comments of the staff of the Commission (the "Staff") or changes to
disclosure in response to Staff comments in the Schedule TO reviewed
by the Staff do not foreclose the Commission from taking any action
with respect to the Schedule TO; and
o the Company may not assert Staff comments as a defense in any
proceeding initiated by the Commission or any person under the federal
securities laws of the United States.
If you have any questions or further comments, please do not hesitate to contact
the undersigned or Katherine J. Blair at (310) 552-5000 or via fax at (310)
552-5001.
Sincerely,
/s/ Michael K. Wilhelm
Michael K. Wilhelm
cc: Katherine J. Blair
John N. Fermanis
Thomas J. Poletti
Michael S. Yu
</TEXT>
</DOCUMENT>